www.businesswire.com Open in urlscan Pro
23.37.36.148  Public Scan

Form analysis
1 forms found in the DOM

Name: bw-search-form — POST /portal/site/home/template.SINGLEPORTLET/action.process/permalink/?javax.portlet.action=true&currentTemplateID=PAGE&javax.portlet.tpst=503a8767054f0df6a9e77a100d908a0c&javax.portlet.begCacheTok=com.vignette.cachetoken&javax.portlet.endCacheTok=com.vignette.cachetoken

<form id="bw-search-form" name="bw-search-form"
  action="/portal/site/home/template.SINGLEPORTLET/action.process/permalink/?javax.portlet.action=true&amp;currentTemplateID=PAGE&amp;javax.portlet.tpst=503a8767054f0df6a9e77a100d908a0c&amp;javax.portlet.begCacheTok=com.vignette.cachetoken&amp;javax.portlet.endCacheTok=com.vignette.cachetoken"
  method="post">
  <fieldset>
    <div id="bw-search-options">
      <h3 id="bw-search-options-head" class="toggler hidden"><span>Search Options</span></h3>
      <div id="bw-search-filter-links" class="togglee">
        <ul>
          <li><a href="#?type=all" id="bw-search-filter-all" title="Search All" class="is-selected">Search All</a></li>
          <li><a href="#?type=news" id="bw-search-filter-news" title="Search News">Search News</a></li>
          <li><a href="#?type=site" id="bw-search-filter-site" title="Search Site">Search Site</a></li>
          <li>
            <a href="/portal/site/home/search?javax.portlet.tpst=503a8767054f0df6a9e77a100d908a0c&amp;javax.portlet.pbp_503a8767054f0df6a9e77a100d908a0c_view=advancedSearch&amp;javax.portlet.begCacheTok=com.vignette.cachetoken&amp;javax.portlet.endCacheTok=com.vignette.cachetoken" id="bw-search-filter-adv" title="Advanced News Search">Advanced News Search</a>
          </li>
        </ul>
      </div>
    </div>
    <label for="bw-search-input">Advanced News Search</label>
    <input type="search" id="bw-search-input" name="q" maxlength="256" value="" title="Search BusinessWire.com" placeholder="Search">
    <input type="hidden" id="bw-search-type" name="qSearchType" value="all">
    <button type="submit" class="bw-button-primary" id="bw-search-button" title="Search"><span><img src="/images/icons/icon_search.gif" alt="Search"></span></button>
  </fieldset>
</form>

Text Content

STEMSON THERAPEUTICS AND BOSLEY PARENT COMPANY, ADERANS, SIGN EXCLUSIVE HAIR
REGENERATION LICENSING DEAL

Stemson to leverage Aderans’ clinical stage hair loss cell therapy program and
expand its hair loss product development pipeline

March 08, 2024 08:00 PM Eastern Standard Time

SAN DIEGO--(BUSINESS WIRE)--Stemson Therapeutics and Aderans Company, the parent
company of Bosley® and HAIRCLUB®, today announced an agreement securing Stemson
the exclusive global rights to research, develop and commercialize hair
regeneration therapeutic products based on Aderans’ proprietary hair
regeneration cell therapy technology. Stemson, a leader in developing a
proprietary cell therapy technology for reversing hair loss based on induced
pluripotent stem cells (iPSC), gains a complementary technology through this
agreement. Stemson will resume Aderans’ Phase 2 clinical stage cell therapy hair
regeneration program, integrate the technology into its existing hair loss cell
therapy development pipeline, and provide multiple products for patients
experiencing hair loss.

> “We believe Stemson, with their advanced expertise in hair follicle cell and
> tissue engineering, is ideally positioned to successfully complete development
> and commercialization of this exciting hair regeneration solution.”
> 
> Post this

Aderans’ proprietary hair regeneration platform is a cell therapy system that
utilizes patient-derived hair and skin cells to durably rejuvenate shrinking
hair follicles in patients with Androgenetic Alopecia by repopulating functional
hair follicle cells into early-to-mid stage hair loss areas. Aderans Co., a
Tokyo-based global leader in hair products and services, conducted Phase 2
clinical testing in the United States on 445 human patients to treat
early-to-mid stage Androgenetic Alopecia in men and women. Initial clinical data
suggest a single dose of functional hair follicle cells into the target scalp
area can safely produce long lasting and durable hair growth results. Stemson
intends to leverage this technology as it continues development of iPSC-derived
autologous cell therapy to regenerate healthy hair follicles. Stemson has
successfully created human hair follicles in humanized mice using engineered
follicular units which are designed to provide an unlimited source of hair
follicle replacements capable of treating a range of hair loss indications.

“The addition of Aderans technology and their Phase 2 clinical stage development
program into the Stemson portfolio enables us to expand our pursuit of multiple
cell therapy product concepts to address a broad range of hair loss
indications,” said Geoff Hamilton, CEO of Stemson Therapeutics. “Aderans’ early
pioneering work in cell therapy for hair loss demonstrated to the field the
potential for durable long lasting hair regeneration results by restoring
functional hair cells and tissue. We are excited to combine their work with our
cell and tissue engineering capabilities in the hair regeneration field to
create truly breakthrough products for hair loss patients. The synergies between
the Aderans technology and Stemson’s in-house technology will help us accelerate
timelines across our programs.”

“Our pioneering work at the Aderans Research Institute to develop the first ever
cell therapy solution for hair loss showed tremendous promise in clinical trials
to treat early stage Androgenetic Alopecia in men and women,” declared Dr. Ken
Washenik, M.D., Ph.D., Chief Medical Officer of Bosley Medical Group, The
World’s Most Experienced Hair Restoration Experts®, and former Chief Executive
Officer of Aderans Research Institute. “We believe Stemson, with their advanced
expertise in hair follicle cell and tissue engineering, is ideally positioned to
successfully complete development and commercialization of this exciting hair
regeneration solution.”

“Aderans has been developing solutions for hair loss since our founding in 1968.
Our agreement with Stemson positions our hair regeneration cell therapy
technology to deliver advanced solutions to serve the global population,” added
Yoshihiro Tsumura, Group CEO, Representative Director, and President of Aderans.
“We look forward to working with the Stemson team to enable their development
efforts and to support the commercialization through our global network of
clinics serving hair loss patients.”

An estimated 80 million men, women, and children in the United States experience
hair loss, which is often associated with emotional distress leading to reduced
quality of life, anxiety, and depression. There are no existing therapeutic
solutions capable of rejuvenating shrinking follicles, nor can they generate new
hair follicles to replace lost hair.

For updates on Stemson’s progress and advancement, please visit www.stemson.com.

About Stemson Therapeutics

Stemson Therapeutics is a pre-clinical stage cell therapy company founded in
2018 with a mission to cure hair loss by leveraging the regenerative power of
Induced Pluripotent Stem Cells. Stemson uses iPSC to regenerate the critical
cells required to grow hair and which are damaged or depleted in patients
suffering from hair loss. The iPSC-derived cells are used to grow de novo hair
follicles, offering a new supply of hair to treat people suffering from various
forms of Alopecia. Today, there are no available treatments capable of growing
new hair follicles. Stemson’s world class team of scientists, advisors and
collaborators are passionate about delivering a scientifically based, clinically
tested cure for hair loss to the millions of hair loss sufferers who seek help
for their hair loss condition. Stemson Therapeutics is headquartered in San
Diego, CA. For more information, please visit www.stemson.com.

About Aderans Company

Aderans Company is a leading global provider of total hair solutions. Founded in
1968 and headquartered in Tokyo, Aderans has built a global presence across
Asia, North America, and Europe to provide a wide range of hair solutions,
including hair care products, advanced wig solutions, hair transplantation
procedures, and non-surgical hair restoration and hair loss prevention services.
Aderans owns well-known brands in North America such as Bosley and HAIRCLUB.
Aderans invests in the research and development of advanced solutions for hair
care and hair loss, which led them to pioneer innovations in cell therapy to
treat hair loss through their Aderans Research Institute subsidiary, including
development of a cell therapy product through Phase 2 clinical trials. For more
information, please visit www.aderans.co.jp.


CONTACTS

Amy Caterina (amy@stemsontx.com) at Stemson Therapeutics 

Group CSR and Corporate Communications Office, Aderans Co., Ltd.
Email: pr@aderans.com    


STEMSON THERAPEUTICS


RELEASE SUMMARY

Stemson secured the exclusive global rights from Aderans to research, develop
and commercialize hair regeneration therapeutic products.


#HASHTAGS

 * #aderans
 * #bosley
 * #CellTherapy
 * #stemson
 * #Phase2
 * #PluripotentStemCells
 * #Alopecia
 * #iPSC
 * #HAIRCLUB
 * #hairloss
 * #stemcell
 * #HairRegeneration
 * #ClinicalTrials


SOCIAL MEDIA PROFILES

 * StemsonTx




MORE NEWS

 * February 06, 2024
   Stemson Therapeutics Announces Technological Breakthrough in New Hair Growth


CONTACTS

Amy Caterina (amy@stemsontx.com) at Stemson Therapeutics 

Group CSR and Corporate Communications Office, Aderans Co., Ltd.
Email: pr@aderans.com    




SITE NAVIGATION

 * Home
   * Home
   * Submit a Press Release
 * Services
 * News
   * All News
   * News with Multimedia
   * News by Industry
   * News by Subject
   * News by Language
   * Tradeshows & Events
 * Education
   * Overview
   * Blog
   * Distribution & Media
   * Media & Journalist Tools
   * Sample Press Release
   * Find Your News Online
   * Disclosure Resources
 * About Us
   * Overview
   * Become a Member
   * Contact Us
   * Careers
   * Business Wire Newsroom
   * Business Wire Events


SEARCH


SEARCH OPTIONS

 * Search All
 * Search News
 * Search Site
 * Advanced News Search

Advanced News Search
 * Log In
 * Sign Up


FOLLOW US

 * Twitter
 * LinkedIn


MORE FROM BUSINESS WIRE

 * Blog
 * UK/Ireland
 * Deutschland
 * France
 * Hong Kong
 * Italy
 * Japan
 * Tradeshownews.com


BUSINESS WIRE INFORMATION

 * Contact Us
 * UK Tax Strategy
 * Privacy Statement
 * Manage Cookies
 * Terms of Use
 * © 2024 Business Wire

Internet Explorer presents a security risk. To ensure the most secure and best
overall experience on our website we recommend the latest versions of Chrome,
Edge, Firefox, or Safari. Internet Explorer will not be supported as of August
17, 2021. Internet Explorer is no longer supported. To ensure the most secure
and best overall experience on our website, we recommend the latest versions of
Chrome, Edge, Firefox, or Safari.


PRIVACY PREFERENCE CENTER

When you visit any website, it may store or retrieve information on your
browser, mostly in the form of cookies. This information might be about you,
your preferences or your device and is mostly used to make the site work as you
expect it to. The information does not usually directly identify you, but it can
give you a more personalized web experience. Because we respect your right to
privacy, you can choose not to allow some types of cookies. Click on the
different category headings to find out more and change our default settings.
However, blocking some types of cookies may impact your experience of the site
and the services we are able to offer. More information
Allow All


MANAGE CONSENT PREFERENCES

STRICTLY NECESSARY COOKIES

Always Active
Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched
off in our systems. They are usually only set in response to actions made by you
which amount to a request for services, such as setting your privacy
preferences, logging in or filling in forms. You can set your browser to block
or alert you about these cookies, but some parts of the site will not then work.
These cookies do not store any personally identifiable information.

Cookies Details‎

FUNCTIONAL COOKIES

Functional Cookies

These cookies enable the website to provide enhanced functionality and
personalisation. They may be set by us or by third party providers whose
services we have added to our pages. If you do not allow these cookies then some
or all of these services may not function properly.

Cookies Details‎

PERFORMANCE COOKIES

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and
improve the performance of our site. They help us to know which pages are the
most and least popular and see how visitors move around the site. All
information these cookies collect is aggregated and therefore anonymous. If you
do not allow these cookies we will not know when you have visited our site, and
will not be able to monitor its performance.

Cookies Details‎

TARGETING COOKIES

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may
be used by those companies to build a profile of your interests and show you
relevant adverts on other sites. They do not store directly personal
information, but are based on uniquely identifying your browser and internet
device. If you do not allow these cookies, you will experience less targeted
advertising.

Cookies Details‎

SOCIAL MEDIA COOKIES

Social Media Cookies

These cookies are set by a range of social media services that we have added to
the site to enable you to share our content with your friends and networks. They
are capable of tracking your browser across other sites and building up a
profile of your interests. This may impact the content and messages you see on
other websites you visit. If you do not allow these cookies you may not be able
to use or see these sharing tools.

Cookies Details‎
Confirm My Choices

Back Button

Back


PERFORMANCE COOKIES

Vendor Search Search Icon Filter Icon


Clear Filters

Information storage and access
Apply
Consent Leg.Interest

All Consent Allowed

Select All Vendors
Select All Vendors
All Consent Allowed


 * 33ACROSS
   
   HOST DESCRIPTION
   
   VIEW COOKIES
   
   
   REPLACE-WITH-DYANMIC-HOST-ID
    * Name
      cookie name


 * 33ACROSS
   
   View Privacy Notice
   
   3 Purposes
   
   REPLACE-WITH-DYANMIC-VENDOR-ID
   Arrow
   
   Consent Purposes
   
   Location Based Ads
   
   Consent Allowed
   
   Legitimate Interest Purposes
   
   Personalize
   
   Require Opt-Out
   
   Special Purposes
   
   Location Based Ads
   
   Features
   
   Location Based Ads
   
   Special Features
   
   Location Based Ads

Confirm My Choices


By clicking “Accept All Cookies”, you agree to the storing of cookies on your
device to enhance site navigation, analyze site usage, and assist in our
marketing efforts. Cookie Policy

Cookies Settings Accept All Cookies




 * Share
 * Share
 * Post
 * Mail
 * Share
 * Copy
 * Share